Bryan Johnson, the entrepreneur at the forefront of the longevity movement, has revealed a new health challenge: a diagnosis of autoimmune gastritis (AIG). Known for his meticulously tracked and expensive regimen aimed at reversing aging, Johnson now faces a condition where his own immune system is attacking his stomach lining.
A Hidden Battle: Autoimmune Gastritis Diagnosis
Despite investing nearly $2 million annually into a comprehensive health protocol involving constant medical surveillance and hundreds of biomarker tests, Johnson confirmed he was silently battling AIG. This diagnosis, confirmed in May through a stomach tissue biopsy, came after years of unexplained low iron levels that baffled standard medical investigations.
Autoimmune gastritis causes the immune system to mistakenly target the stomach's acid-producing cells. Current medical understanding largely considers AIG incurable, with treatment typically focusing on managing symptoms and monitoring for complications.
Years of Unexplained Iron Deficiency
The first indication of trouble emerged over a decade ago when routine health checks consistently showed abnormally low ferritin, the protein responsible for storing iron in the body. Despite a carefully controlled plant-based diet, intense exercise, and various iron supplements, Johnson's iron reserves never recovered.
Initially, factors like his demanding lifestyle were suspected to increase iron demand. However, a deeper cause remained elusive. Earlier this year, a rebuilt medical team revisited his history of autoimmune thyroid disease, prompting an investigation into thyrogastric syndrome, a condition where autoimmune thyroid and gastritis often coexist.
Uncovering the Disease
To rule out internal bleeding, Johnson underwent a colonoscopy, which showed no abnormalities. Concurrently, doctors performed an upper endoscopy, ordered multiple stomach biopsies, and measured immune biomarkers. Blood tests revealed anti-parietal cell antibodies at nearly five times the normal limit, strongly indicating autoimmune gastritis. Subsequent tissue biopsies confirmed early-stage autoimmune damage.
Johnson noted that the disease likely would have remained undetected if doctors had relied solely on visual examination during the endoscopy, as there were no obvious signs of damage.
Why AIG Often Goes Undiagnosed
Autoimmune gastritis progresses slowly, often without noticeable symptoms until significant damage has occurred. It impairs the stomach's ability to produce acid, hindering the absorption of vital nutrients like iron and vitamin B12. Over time, this can lead to anemia and an increased risk of stomach cancer.
Johnson argues that a key reason for missed diagnoses is a medical tendency to focus on hemoglobin levels rather than ferritin. Since the body depletes stored iron before hemoglobin levels drop, individuals can suffer from iron deficiency for years while standard blood counts appear normal.
Challenging Conventional Medicine
Following his diagnosis, Johnson received an intravenous iron infusion to correct his deficiency. However, he emphasizes that treating the underlying autoimmune disease presents a far greater challenge than merely managing symptoms.
Rather than accepting AIG as a lifelong condition to be managed, Johnson and his team have outlined an ambitious research roadmap. This plan includes rigorous monitoring of biomarkers, detailed immune profiling through repeat biopsies and cellular analysis, and eventually, the exploration of targeted therapies. These advanced approaches could involve inflammatory signaling pathways, immune-cell regulation, and cutting-edge engineered treatments like CAAR-T cell therapy and AI-designed biological therapies. Johnson acknowledges that many of these advanced methods are experimental or still under development.
A Broader Message and Call for Collaboration
Johnson's diagnosis reinforces his belief that the absence of symptoms should not be mistaken for good health. He also posits that advancements in artificial intelligence, genomics, and cell engineering warrant a re-evaluation of diseases traditionally deemed incurable.
He is now actively inviting researchers specializing in autoimmune gastritis, immune tolerance, regulatory T cells, and engineered immune therapies to collaborate. His hope is that his personal battle could contribute to reshaping the broader treatment landscape for autoimmune diseases.